# Jamie E. Chaft

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jamie-e-chaft/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,982 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 70 |
| i10-index | 165 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5090385143 |
| ORCID iD | https://orcid.org/0000-0002-5838-9982 |
| Works | 572 |

## Researcher papers

Showing 12 of 20.

- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing](https://scholariq.org/papers/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti/)
- [Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy](https://scholariq.org/papers/pneumonitis-in-patients-treated-with-anti-programmed-death-1-programmed-death/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/impact-of-baseline-steroids-on-efficacy-of-programmed-cell-death-1-and/)
- [Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis](https://scholariq.org/papers/serpins-promote-cancer-cell-survival-and-vascular-co-option-in-brain-metastasis/)
- [Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies](https://scholariq.org/papers/prospective-comprehensive-molecular-characterization-of-lung-adenocarcinomas-for/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer](https://scholariq.org/papers/structural-biochemical-and-clinical-characterization-of-epidermal-growth-factor/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.